相关实验视频
Updated: Jul 19, 2025

07:51
Refined Murine Model of Idiopathic Pulmonary Fibrosis
Published on: June 17, 2025
141
异形性肺纤维化和患者对皮尔芬尼的反应的遗传变异
Aahd Kubbara1, William H Amundson2, Adam Herman3
1Department of Medicine, Division of Pulmonary, Allergy, Critical Care, and Sleep, University of Minnesota, Minneapolis, United States.
Heliyon
|August 10, 2023
概括
异形性肺纤维化 (IPF) 患者的遗传变异会影响皮尔芬尼治疗结果. 特定的TOLLIP和TGF-B1基因变异可能会改善接受皮尔芬尼治疗的IPF患者的生存率.
科学领域:
- 肺部医学 肺部医学
- 药物基因组学 药物基因组学
- 遗传学 遗传学 是一个
背景情况:
- 异形性肺纤维化 (IPF) 是一种进展性肺部疾病,患者的结局变化不定.
- 目前对抗纤维菌疗法的管理依赖于副作用概况.
- 遗传变异,包括单核酸多态 (SNP),可能会影响IPF患者的治疗反应和生存.
研究的目的:
- 研究特定遗传变异与IPF患者对皮尔芬尼治疗的患者反应之间的关联.
- 探索患者特异性遗传特征如何影响皮尔芬尼治疗的生存结果.
主要方法:
- 来自56名IPF患者的临床数据的回顾性分析.
- 对已知与IPF结果或pirfenidone代谢相关的9个选定的SNP进行DNA提取和基因定型.
- 基因变异与临床数据和皮尔芬尼治疗结果的相关性.
主要成果:
- 在 pirfenidone 治疗期间,TOLLIP rs5743890 风险等位基因 (CC 或 CT 基因型) 与改善的存活率显著相关 (p=0.0457).
- 此外,TGF-B1 rs1800470风险等位基因与更长时间的皮尔费尼治疗 (p=0.0395),尽管与疾病进展有关,但与更好的生存率有显著的关联.
- 患者人口统计包括67.85%的男性,诊断时平均年龄为66.88岁.
结论:
- 这项试点研究表明,TOLLIP rs5743890 (CC,CT) 和TGF-B1 rs1800470的特定基因型可以预测IPF患者治疗pirfenidone的生存率增加.
- 这些发现强调了药物遗传学在个性化IPF治疗策略方面的潜在作用.
相关概念视频
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.8K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.8K
Pulmonary Hypertension: Classification and Pathogenesis
223
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
223
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
2.5K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
2.5K
iPS Cell Differentiation
2.7K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
215
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
215
COPD: Pathogenesis and Clinical Features
344
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
344

